BEST UNLIMITED TURBO LONG CERTIFICATE - MEDTRONIC Stock

Certificat

NF02S

DE000SH0XQN1

Market Closed - Euronext Paris 12:30:00 2024-04-29 pm EDT
2.148 EUR +14.50% Intraday chart for BEST UNLIMITED TURBO LONG CERTIFICATE - MEDTRONIC
Current month-36.95%
1 month-36.95%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
24-04-29 2.148 +14.50% 57
24-04-26 1.876 +2.12% 52
24-04-25 1.837 -13.14% 46
24-04-24 2.115 -1.90% 67
24-04-23 2.156 +6.47% 45

Real-time Euronext Paris

Last update April 29, 2024 at 12:30 pm EDT

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
NF02S
ISINDE000SH0XQN1
Date issued 2021-12-20
Strike 69.8 $
Maturity Unlimited
Parity 5 : 1
Emission price 6.96
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 9.579
Lowest since issue 0.434

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
80.86 USD
Average target price
94.75 USD
Spread / Average Target
+17.18%
Consensus
  1. Stock Market
  2. Certificates
  3. NF02S Certificat